No Detail Found!

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.

Author(s)
Feng Xian-Jun Department of Respiratory Medicine, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China
Qin Xiu-Guang Department of Thoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China
Zang Li Combine Traditional Chinese and Western Medicine Dept, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China
Feng Hui Combine Traditional Chinese and Western Medicine Dept, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China
Wang Wan-Ling Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China
Liu Dong Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China
Li Ping-Fa Inspection Department, Xinxiang Medical University, Xinxiang, China
Abstract
Objective: We conducted a perspective study to investigate the association between mRNA expression quantities of ERCC1, BRCA1, RRM1 and RRM2 and response to chemotherapy and clinical outcome of advance Non-Small Cell Lung Cancer.(NSCLC). Methods: Two hundred eight patients who were diagnosed as advanced stage NSCLC were included in our study. A fluorescence-based and real-time detection method was used to determine the relative cDNA quantification for ERCC1, BRCA1, RRM1 and RRM2, and β-actin was used as the reference gene. Results: The median expression levels of ERCC1, BRCA1, RRM1 and RRM2 mRNA were 0.67±0.17, 0.095±0.012, 0.24±0.17 and 2.45±0.32, respectively. Our study found that the low ERCC1 (OR=1.82, 95% CI=1.01-3.20) and Low BRCA1 (OR=2.53, 95%CI=1.38-4.64) mRNA expression was more likely to response to chemotherapy when compared with high expression, respectively. Multivariate Cox regression analysis indicated that patients with low mRNA expression of ERCC1 and BRCA1 attained 0.43 (OR=0.43, 95%CI=0.27-0.89) and 0.37 (OR=0.37, 95%CI=0.22-0.66) fold risk of death from NSCLC. However, we found RMM1 and RRM2 mRNA expression could not influence the response to chemotherapy and clinical outcome of NSCLC. Conclusion: ERCC1 and BRCA1 mRNA expression could be important predictive markers for individualized platinum-based chemotherapy for NSCLC patients.
Publication Details
Page(s) 488-492
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 30, Issue: 3, Year: 2014

Request the full text from PASTIC

0

Citations

0

Downloads

98

Views